Cutamesine (SA4503) is a selective sigma-1 receptor agonist, currently in Phase II clinical trials for depression and post stroke neurological disturbances. Cutamesine has been found to be effective in several rodent models of amnesia and depression. We used data obtained with carbon-11-labeled cutamesine (11CSA4503) in rats to develop a population pharmacokinetic (PK) model. Nonlinear mixed effects modeling (NONMEM) provides a tool for analyzing repeated measurements data in which the relationship between the explanatory and response variables can be modeled as a single function, allowing the parameters to differ between individuals. This modeling framework can be useful to scale preclinical drug kinetic information to clinical settings. M...
A pharmacokinetic (PK) model was developed for nusinersen, an antisense oligonucleotide (ASO) that i...
Clinical development of drugs for central nervous system (CNS) disorders has been particularly chall...
The histamine H3 receptor has been considered as a target for the treatment of various central nervo...
Cutamesine (SA4503) is a selective sigma-1 receptor agonist, currently in Phase II clinical trials f...
RATIONALE: Sigma-1 receptor agonists are under investigation as potential disease-modifying agents f...
BACKGROUND: Preferred models for the pharmacokinetic analysis of [11C]flumazenil human studies have ...
The sigma-1 receptor is a unique orphan receptor, strongly expressed in neurons and glia. Sigma-1 re...
The sigma-1 receptor is a unique orphan receptor, strongly expressed in neurons and glia. Sigma-1 re...
Background: Preferred models for the pharmacokinetic analysis of [C-11] flumazenil human studies hav...
Purpose: Changes in GABAA-receptor density and affinity play an important role in many forms of epil...
Preferred models for the pharmacokinetic analysis of [(11)C]flumazenil human studies have been previ...
Rapid eye movement (REM) sleep deprivation (SD) decreases cerebral sigma-1 receptor expression and c...
Purpose: Sigma-1 receptor ligands modulate the release of several neurotransmitters and intracellula...
Background and Objective: p75ECD-Fc is a novel antagonist of toxic amyloid beta protein and other ne...
Rapid eye movement (REM) sleep deprivation (SD) decreases cerebral sigma-1 receptor expression and c...
A pharmacokinetic (PK) model was developed for nusinersen, an antisense oligonucleotide (ASO) that i...
Clinical development of drugs for central nervous system (CNS) disorders has been particularly chall...
The histamine H3 receptor has been considered as a target for the treatment of various central nervo...
Cutamesine (SA4503) is a selective sigma-1 receptor agonist, currently in Phase II clinical trials f...
RATIONALE: Sigma-1 receptor agonists are under investigation as potential disease-modifying agents f...
BACKGROUND: Preferred models for the pharmacokinetic analysis of [11C]flumazenil human studies have ...
The sigma-1 receptor is a unique orphan receptor, strongly expressed in neurons and glia. Sigma-1 re...
The sigma-1 receptor is a unique orphan receptor, strongly expressed in neurons and glia. Sigma-1 re...
Background: Preferred models for the pharmacokinetic analysis of [C-11] flumazenil human studies hav...
Purpose: Changes in GABAA-receptor density and affinity play an important role in many forms of epil...
Preferred models for the pharmacokinetic analysis of [(11)C]flumazenil human studies have been previ...
Rapid eye movement (REM) sleep deprivation (SD) decreases cerebral sigma-1 receptor expression and c...
Purpose: Sigma-1 receptor ligands modulate the release of several neurotransmitters and intracellula...
Background and Objective: p75ECD-Fc is a novel antagonist of toxic amyloid beta protein and other ne...
Rapid eye movement (REM) sleep deprivation (SD) decreases cerebral sigma-1 receptor expression and c...
A pharmacokinetic (PK) model was developed for nusinersen, an antisense oligonucleotide (ASO) that i...
Clinical development of drugs for central nervous system (CNS) disorders has been particularly chall...
The histamine H3 receptor has been considered as a target for the treatment of various central nervo...